This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Brian Vastag

JAMA. 2002;287:969-970.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Washington—Clinicians need to brace themselves for another round in the protracted debate over the value of routine prostate-specific antigen (PSA) screening. A new study from Stanford University School of Medicine contends that PSA scores between 2 ng/mL and 9 ng/mL are "clinically useless" in predicting the size and aggressiveness of prostate tumors. The group, led by Thomas Stamey, MD, also concludes that PSA values in that middle range "have a limited relationship with [surgical] cure rates" (J Urology. 2002;167:103-111).

The report has triggered intense responses from both sides of a deep clinical rift.

"I don't want to use the word dangerous, but my concern about this article is the bottom line message of not worrying about PSA until it is in the 7 to 9 range," said William Catalona, MD, a urologic surgeon at Washington University School of Medicine, St Louis, who performs biopsies on patients . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Liability for Failure to Order Screening Examinations
Berlin
Am. J. Roentgenol. 2002;179:1401-1405.
FULL TEXT